Lanthanum Carbonate (Fosrenol®) and Sevelamer Carbonate (Renvela®) Application with Prescription



PLEASE MAKE SURE THIS FORM IS CO-SIGNED BEFORE FAXING TO THE PHARMACY.

Health Authority:		Name:				
Dialysis Modality: ☐ Centre HD	☐ Community HD		Home HD	□ CAP	D □ C(`DD
	reasonable adherer					,,,,
yes		ice with on	iei piiospiiate	Jilidel allu	ulet tilerapy.	
Patient has been tr	ialed on calcium ac	etate to red	uce hypercalce	mia:		
□ yes	□ no					
Patient is on a 1.25 calcium dialysate: □ yes □ noIf not, enter calcium bath concentration □ N/A (PD patient)						
Vitamin D analogu	e dose has been red	uced to rec	luce hypercalco	emia:		
□ yes	□ no	□ not appli	cable			
☐ Maximal standard therapy with calcium based binders has been unsuccessful.						
□ Sevelamer carbonate 800 mg (1 tab) PO TID at the beginning of meals (90 tabs) □ Lanthanum 250 mg TID with or at the end of meals (90 tabs) □ Other: Note: Community pharmacist must not fill this prescription without two signatures below. (New prescription for 30 days with two refills of 60 days each allowed. Total days supply = 150) Calcium-based phosphate binders remain the first and cheapest option. Lanthanum should be prescribed only in situations where sevelamer carbonate has failed or is not an option. Using lanthanum represents a significant						
increase in the cost of therapy.						
☐ If lanthanum o disclosed to the Signature:	r sevelamer is to be patient this non- Renal Dietitia (reasonable diet adl	Health Cai		d use.	phrologist or Rena	ognized and have
	,	,			,	,
Print Name:	n nerence)	Nephrologist or Renal Clinical Pharmacist (reasonable medication adherence)				
DATE (DD/MM/YYYY)	PRESCRIBER NAME (I	PRINTED)	PRESCRIBER SIG	GNATURE	COLLEGE ID	CONTACT NUMBER

BC Renal • BCRenalAgency.ca Revised July 2020 1 of 1